Showing results (31-40 of 108) with videos related to

Sort By:
Pageof 11
Journal of Cancer Research and Clinical Oncology|December 18, 2017
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuationFranco Trevisani, Giovanni Brandi, Francesca Garuti, et al.
Annals of Hepatology|May 27, 2020
Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population?Francesco Giuseppe Foschi, Marco Domenicali, Pierluigi Giacomoni, et al.
Journal of Clinical Medicine|February 4, 2021
External Validation of Surrogate Indices of Fatty Liver in the General Population: the Bagnacavallo StudyFrancesco Giuseppe Foschi, Fabio Conti, Marco Domenicali, et al.
Journal of Clinical Medicine|September 10, 2021
Model of Care for Microelimination of Hepatitis C Virus Infection among People Who Inject DrugsFrancesco Giuseppe Foschi, Alberto Borghi, Alberto Grassi, et al.
BMC Gastroenterology|November 30, 2018
Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo StudyFrancesco Giuseppe Foschi, Giorgio Bedogni, Marco Domenicali, et al.
Expert Opinion on Pharmacotherapy|October 30, 2015
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenibAndrea Casadei Gardini, Giorgia Marisi, Emanuela Scarpi, et al.
Oncotarget|April 9, 2016
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS studyAndrea Casadei Gardini, Giorgia Marisi, Luca Faloppi, et al.
Pageof 11